Glomerular mesangial cell recruitment and function require the co-receptor neuropilin-1

Proteinuria has been reported in cancer patients receiving agents that target the transmembrane receptor neuropilin-1 (Nrp1) suggesting potential adverse effects on glomerular function. Here we show that Nrp1 is highly expressed by mesangial cells and that genetic deletion of the gene from PDGF rece...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Renal physiology Vol. 313; no. 6; pp. F1232 - F1242
Main Authors Bartlett, Christina S, Scott, Rizaldy P, Carota, Isabel Anna, Wnuk, Monika L, Kanwar, Yashpal S, Miner, Jeffrey H, Quaggin, Susan E
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.12.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Proteinuria has been reported in cancer patients receiving agents that target the transmembrane receptor neuropilin-1 (Nrp1) suggesting potential adverse effects on glomerular function. Here we show that Nrp1 is highly expressed by mesangial cells and that genetic deletion of the gene from PDGF receptor-β mesangial cells results in proteinuric disease and glomerulosclerosis, leading to renal failure and death within 6 wk of age in mice. The major defect is a failure of mesangial cell migration that is required to establish the mature glomerular tuft. In vitro data show that the potent chemotactic effect of PDGFB is lost in Nrp1-deficient mesangial cells. Biochemical analyses reveal that Nrp1 is required for PDGFB-dependent phosphorylation of p130 Crk-associated substrate (p130Cas), a large-scaffold molecule that is involved in motility of other cell types. In stark contrast, matrix adhesion and activation of ERK and Akt, which mediate proliferation of mesangial cells in response to PDGFB, are unaffected by the absence of Nrp1. Taken together, these results identify a critical cell-autonomous role for Nrp1 in the migratory behavior of mesangial cells and may help explain the renal effects that occur in patients receiving Nrp1-inhibitory drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1931-857X
1522-1466
DOI:10.1152/ajprenal.00311.2017